LIDOCAINE INJECTION BP SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

LIDOCAINE HYDROCHLORIDE

Pieejams no:

EUGIA PHARMA INC.

ATĶ kods:

N01BB02

SNN (starptautisko nepatentēto nosaukumu):

LIDOCAINE

Deva:

1%

Zāļu forma:

SOLUTION

Kompozīcija:

LIDOCAINE HYDROCHLORIDE 1%

Ievadīšanas:

BLOCK/INFILTRATION

Vienības iepakojumā:

100

Receptes veids:

Ethical

Produktu pārskats:

Active ingredient group (AIG) number: 0101280004; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2022-09-02

Produkta apraksts

Page 1 of 29
PRESCRIBING INFORMATION
LIDOCAINE INJECTION BP
LIDOCAINE HYDROCHLORIDE
1% w/v (10 mg/mL) and 2% w/v (20 mg/mL)
Sterile solution for injection
[With Preservative]
Local Anesthetic
EUGIA PHARMA INC
Date of Preparation:
3700 Steeles Avenue West, Suite # 402
SEPT 2, 2022
Woodbridge, Ontario, L4L 8K8
Canada
Submission Control No: 265490
Page 2 of 29
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.................................................................... 3
INDICATIONS AND CLINICAL USE
..........................................................................
3
CONTRAINDICATIONS
...............................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................
4
ADVERSE REACTIONS
..............................................................................................
10
DRUG INTERACTIONS
..............................................................................................
12
DOSAGE AND ADMINISTRATION
..........................................................................
14
OVERDOSAGE
............................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
........................................................ 18
STORAGE AND STABILITY
......................................................................................
20
SPECIAL HANDLING INSTRUCTIONS
................................................................... 20
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................... 21
PART II: SCIENTIFIC INFORMATION
...............................................................................
22
PHARMACEUTICAL INFORMATION
......................................................................
22
REFERENCES
..................................................................